Claro Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Claro Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$439K	Buy	568 +11	+2%	+$8.42K	0.05%	271
2025 Q4	$430K	Buy	557 +102	+22%	+$69.3K	0.06%	255
2025 Q3	$256K	Buy	+455	New	+$257K	0.04%	342
2025 Q2	–	Sell	-620	Closed	-$393K	–	481
2025 Q1	$393K	Buy	620 +217	+54%	+$149K	0.05%	321
2024 Q4	$287K	Sell	403 -75	-16%	-$62.9K	0.04%	371
2024 Q3	$502K	Buy	478 +251	+111%	+$279K	0.06%	266
2024 Q2	$239K	Buy	+227	New	+$220K	0.04%	368
2019 Q1	–	Sell	-2	Closed	-$1K	–	762
2018 Q4	$1K	Buy	+2	New	+$732	﹤0.01%	1055

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Claro Advisors's REGN Position: Q1 2026 in Review

Claro Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 2% in Q1 2026, buying an estimated $8.42K and bringing the position to 568 shares worth $439K. The position accounts for 0.05% of the portfolio, ranked #271.

Claro Advisors first reported a position in REGN in Q4 2018 and has held it in 8 quarters since. The position peaked at $502K in Q3 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Claro Advisors held 568 shares of Regeneron Pharmaceuticals worth $439K as of Q1 2026.
Claro Advisors bought 11 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $8.42K.
Regeneron Pharmaceuticals made up 0.05% of Claro Advisors's portfolio in Q1 2026, its #271 holding.
Claro Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2018 and has held it in 8 quarters since.
Claro Advisors's Regeneron Pharmaceuticals position peaked at $502K in Q3 2024.
1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Claro Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.